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Background:  Iron deficient erythropoiesis due to defectively mobilised (anemia of chronic disease [ACD]) and/or depleted (iron deficiency 
anemia [IDA]) stores is the commonest cause of anemia. However, despite the dire implications of anemia in chronic heart failure (CHF), few 
studies have utilised simple iron indices to discriminate IDA from ACD, and to identify IDA in the midst of ACD. Consequently, it is unclear whether the 
etiologies of anemia vary with disease severity or whether improved iron status over time confers a survival advantage.
Methods:  We identified 134 anemic CHF patients (pts) with available iron indices. IDA (transferrin saturation (TSAT) <20%, ferrtin ≤30 μg/L), ACD 
(TSAT<20%, ferritin >30 μg/L, TIBC<65 μmol/L) and ACD+IDA (TSAT<20%, ferritin >30 μg/L, TIBC≥65 μmol/L) were diagnosed.
Results:  At baseline ACD, ACD+IDA, IDA and a non-iron deficient anemia (NIDA) were evident in 52%, 9%, 9% and 29% of hospitalized, and 28%, 
10%, 13%, and 48% of non-hospitalized pts. ACD increased whilst NIDA decreased in prevalence with NYHA class (Fig A). Over a median (±IQR) 
follow-up of 14±18 months, 61 pts had repeat iron studies and 22 (36%) died. Increasing levels of TSAT over time related to better survival (HR 
0.95, 95% CI 0.92-0.98, P=0.002) independently of NYHA class, LVEF and baseline TSATs (Fig B).
Conclusions:  The origins of anemia in CHF vary with disease severity and an improved iron status 
confers prognostic benefits. Large scale iron repletion trials are needed to corroborate these findings. 
